CN115054664A - 一种治疗癌性疼痛的药物组合物及其制备方法 - Google Patents
一种治疗癌性疼痛的药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN115054664A CN115054664A CN202210884533.5A CN202210884533A CN115054664A CN 115054664 A CN115054664 A CN 115054664A CN 202210884533 A CN202210884533 A CN 202210884533A CN 115054664 A CN115054664 A CN 115054664A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- raw
- asparagus
- pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 37
- 206010058019 Cancer Pain Diseases 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 241000227129 Aconitum Species 0.000 claims abstract description 34
- 239000007788 liquid Substances 0.000 claims abstract description 30
- 239000000706 filtrate Substances 0.000 claims abstract description 29
- 241000234427 Asparagus Species 0.000 claims abstract description 25
- 235000005340 Asparagus officinalis Nutrition 0.000 claims abstract description 25
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 25
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 25
- 241001233914 Chelidonium majus Species 0.000 claims abstract description 24
- 238000001914 filtration Methods 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 23
- QMGVPVSNSZLJIA-UHFFFAOYSA-N Nux Vomica Natural products C1C2C3C4N(C=5C6=CC=CC=5)C(=O)CC3OCC=C2CN2C1C46CC2 QMGVPVSNSZLJIA-UHFFFAOYSA-N 0.000 claims abstract description 19
- 244000107975 Strychnos nux-vomica Species 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000012545 processing Methods 0.000 claims abstract description 13
- 238000002156 mixing Methods 0.000 claims abstract description 12
- 239000012467 final product Substances 0.000 claims abstract description 6
- 239000012528 membrane Substances 0.000 claims abstract description 6
- 208000002193 Pain Diseases 0.000 claims description 36
- 230000036407 pain Effects 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 241000173529 Aconitum napellus Species 0.000 claims description 3
- 229940023019 aconite Drugs 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 2
- 238000004140 cleaning Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 230000000202 analgesic effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 231100000331 toxic Toxicity 0.000 description 7
- 230000002588 toxic effect Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229940035676 analgesics Drugs 0.000 description 6
- 239000000730 antalgic agent Substances 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical compound C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 229960005181 morphine Drugs 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 description 2
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- DPMGVDIWDTYPMP-UHFFFAOYSA-N Hypaconitine Natural products COCC12CCC(OC)C3(CN(C)C1)C4CC5(O)C(OC)C(O)C(CC(OC)C23)(OC(=O)C)C4C5OC(=O)c6ccccc6 DPMGVDIWDTYPMP-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940039750 aconitine Drugs 0.000 description 2
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- GHKISGDRQRSCII-UHFFFAOYSA-N chelidonine Natural products C1=C2C3N(C)CC4=C(OCO5)C5=CC=C4C3C(O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-UHFFFAOYSA-N 0.000 description 2
- FIDOCHXHMJHKRW-GKVQVCCJSA-N hypaconitine Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@]45[C@@H](OC)CC[C@@]6([C@H]4[C@@H](OC)[C@H]([C@@](OC(C)=O)([C@H]31)[C@@H](O)[C@H]2OC)[C@H]5N(C)C6)COC)C(=O)C1=CC=CC=C1 FIDOCHXHMJHKRW-GKVQVCCJSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- GPTFURBXHJWNHR-UHFFFAOYSA-N protopine Chemical compound C1=C2C(=O)CC3=CC=C4OCOC4=C3CN(C)CCC2=CC2=C1OCO2 GPTFURBXHJWNHR-UHFFFAOYSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WZRCQWQRFZITDX-UHFFFAOYSA-N (RS)-norcoclaurine Chemical compound C1=CC(O)=CC=C1CC1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- WZRCQWQRFZITDX-AWEZNQCLSA-N Norcoclaurine Natural products C1=CC(O)=CC=C1C[C@H]1C2=CC(O)=C(O)C=C2CCN1 WZRCQWQRFZITDX-AWEZNQCLSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- GTRPODKMSBFDOI-UHFFFAOYSA-N Protopine Natural products CN1Cc2c3OCOc3ccc2C4C1Cc5cc6OCOc6cc5C4=O GTRPODKMSBFDOI-UHFFFAOYSA-N 0.000 description 1
- ZAALQOFZFANFTF-UHFFFAOYSA-N Pseudoprotipine Natural products C1=C2C(=O)CC3=CC=4OCOC=4C=C3CN(C)CCC2=CC2=C1OCO2 ZAALQOFZFANFTF-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000009125 Sigmoid Neoplasms Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- CHWPMFMUQATVNK-ARYYTZDLSA-N dihydrosporogen AO-1 Natural products O[C@H]1[C@]2(C(C)=C)O[C@@H]2[C@]2(C)[C@@H](C)[C@H](O)CCC2=C1 CHWPMFMUQATVNK-ARYYTZDLSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- GQRPJUIKGLHLLN-VSTHTWNCSA-N mesaconine Chemical compound COC[C@]12CN(C)C3[C@@H]4[C@H](OC)[C@H]1[C@]3([C@@H]1C[C@@]3(O)[C@H](O)[C@@H]1[C@]4(O)[C@@H](O)[C@@H]3OC)[C@H](C[C@H]2O)OC GQRPJUIKGLHLLN-VSTHTWNCSA-N 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 201000003825 sigmoid colon cancer Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/56—Loganiaceae (Logania family), e.g. trumpetflower or pinkroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗癌性疼痛的药物组合物及其制备方法,所述药物组合物由下述重量份的原料制备得到:芦笋5‑10份、生附子10‑12份、白屈菜5‑9份、三七3‑5份、马钱子0.6‑1份、生草乌3–6份;所述药物组合物的制备方法,包括以下步骤:1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;2)然后按重量份取用芦笋、白屈菜、三七,并加入到所得初加工液体中,进行两次煎煮,每次煎煮后过滤取其滤液;将两次所得滤液合并,得煎煮提取液;3)将所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
Description
技术领域
本发明涉及一种药物组合物,具体是指一种治疗癌性疼痛的药物组合物及其制备方法。
背景技术
癌症发病率在我国逐年增高,癌痛作为恶性肿瘤后期患者最常见、最痛苦的症状之一,癌痛是由癌症本身和癌症治疗过程(包括手术、放疗、化疗等)有关的以及精神、心理、社会和经济等多种原限所致。它常使患者的生活质量受到严重影响,患者甚至因癌痛而自杀,世界卫生组织和国际疼痛学会根据癌痛现状制定出“三阶梯止痛方案”,虽然在一定程度上使癌痛患者的痛苦得到减轻;
但因杜冷丁和吗啡的临床使用受政策法规、社会人文等多种因素的制约,由于杜冷丁、吗啡耐药和副作用,致使癌性疼痛症状的控制仍不令人满意,癌痛口服液即没有杜冷丁和吗啡的成瘾和耐药等副作用,又有良好的镇痛效果。疼痛复发再次治疗效果依然非常理想;
因此,寻找一种能有效缓解癌性疼痛,又无明显毒副作用的药物,虽然可能只是一种理想化的追求目标,但中医认为癌性疼痛与痰浊内停,阻碍气血运行有关的理论,则为发掘中医中药治疗癌性疼痛提供了一条治疗途径,因此充分发挥祖国医学的优势,结合现代研究成果,开发中医中药作为一种协同方法治疗癌性疼痛,并寻找更为有效,更为安全,以及毒副作用更小的药物,是本发明的意义所在。
发明内容
本发明要解决的技术问题是克服上述技术的缺陷,提供一种治疗癌性疼痛的药物组合物及其制备方法。
为解决上述技术问题,本发明提供的技术方案为一种治疗癌性疼痛的药物组合物,所述药物组合物由下述重量份的原料制备得到:芦笋5-10份、生附子10-12份、白屈菜5-9份、三七3-5份、马钱子0.6-1份、生草乌3–6份。
进一步地,所述药物组合物由下述重量份的原料制备得到:芦笋5份、生附子10份、白屈菜5份、三七3份、马钱子0.6份、生草乌3份。
进一步地,所述药物组合物由下述重量份的原料制备得到:芦笋7份、生附子11份、白屈菜7份、三七4份、马钱子0.8份、生草乌4份。
进一步地,所述药物组合物由下述重量份的原料制备得到:芦笋10份、生附子12份、白屈菜9份、三七5份、马钱子1份、生草乌6份。
本发明还提供了一种治疗癌性疼痛的药物组合物的制备方法,其特征在于,包括以下步骤:
步骤1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;
步骤2)然后按重量份取用芦笋、白屈菜、三七,并加入到步骤1所得初加工液体中,进行两次煎煮;第一次煎煮时,加水量为原料总重量的3-5倍,煎煮60min,过滤后取其滤液;第二次煎煮时,加水量为原料总重量的3-4倍,煎煮50min,过滤后取其滤液;将两次所得滤液合并,得煎煮提取液;
步骤3)将步骤2所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
本发明所用原料来源如下:
芦笋:味甘,寒,无毒;治热病口渴,淋病,小便不利,解诸鱼之毒。
生附子:辛、甘,大热,有毒;归心、肾,脾经;回阳救逆,补火助阳,逐风寒湿邪。治亡阳虚脱,肢冷脉微,阳萎,宫冷,心腹冷痛,虚寒吐泻,阴寒水肿,阳虚外感,寒湿痹痛。此外生附子含乌头碱、次乌头碱、中乌头碱及消旋去甲乌药碱,具有镇痛、镇静的功效。
白屈菜:苦、辛,微温,有毒;归肺、脾、胃经;镇痛,止咳祛痰,利尿解毒;用于镇痛、止咳、利尿、解毒、主胃痛、腹痛、肠炎、痢疾、慢性支气管炎、百日咳、咳嗽、黄疸、水肿、腹水、疥癣疮肿、蛇虫咬伤。此外白屈菜含多种生物碱,其中有白屈菜碱(Chelidonine)、a"原阿片碱,另外根和花还含有其它生物碱,具有解痉、止痛功效。
三七:甘、微苦,温,有小毒;归肝、胃、大肠经;止血,散瘀,消肿,定痛;主治止血,散瘀,止痛,活血,消肿,疗治胃癌,肺癌,,骨肉瘤,直肠癌,乙状结肠癌所致之疼痛岀血等。
马钱子:苦、寒、有小毒;入肝、脾经;散血热,消肿,止痛;治食管癌、胃癌、肠,癌、肺癌、皮肤癌、白血病等;外用治皮肤癌、瘪病痰核、喉痹、风湿痹痛、跌打损伤。
生草乌:辛、苦,热,有毒(生草乌有大毒);归心、肝、脾、肾经;祛风除湿,温经止痛。治风寒湿痹。此外生草乌的块根含乌头碱、次乌头碱、新乌头戚,具有镇痛的功效。
本发明与现有技术相比的优点在于:本发明所提供的治疗癌性疼痛的药物组合物,其全方结构合理,配伍精当,无明显毒副作用,具有防止癌细胞扩散转移和血栓形成,可抑制癌细胞释放5-羟色氨等致炎致痛等化学有害因子对正常细胞与神经的损害;同时还具有活血化瘀作用,从而达到不通则痛,通则不痛的治疗目的。
具体实施方式
下面结合实施例对本发明一种治疗癌性疼痛的药物组合物及其制备方法做进一步的详细说明。
实施例1
一种治疗癌性疼痛的药物组合物,所述药物组合物由下述重量份的原料制备得到:芦笋5份、生附子10份、白屈菜5份、三七3份、马钱子0.6份、生草乌3份;
所述药物组合物的制备方法,其特征在于,包括以下步骤:
步骤1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;
步骤2)然后按重量份取用芦笋、白屈菜、三七,并加入到步骤1所得初加工液体中,进行两次煎煮;第一次煎煮时,加水量为原料总重量的3-5倍,煎煮60min,过滤后取其滤液;第二次煎煮时,加水量为原料总重量的3-4倍,煎煮50min,过滤后取其滤液;将两次所得滤液合并,得煎煮提取液;
步骤3)将步骤2所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
实施例2
一种治疗癌性疼痛的药物组合物,所述药物组合物由下述重量份的原料制备得到:芦笋7份、生附子11份、白屈菜7份、三七4份、马钱子0.8份、生草乌4份;
所述药物组合物的制备方法,其特征在于,包括以下步骤:
步骤1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;
步骤2)然后按重量份取用芦笋、白屈菜、三七,并加入到步骤1所得初加工液体中,进行两次煎煮;第一次煎煮时,加水量为原料总重量的3-5倍,煎煮60min,过滤后取其滤液;第二次煎煮时,加水量为原料总重量的3-4倍,煎煮50min,过滤后取其滤液;将两次所得滤液合并,得煎煮提取液;
步骤3)将步骤2所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
实施例3
一种治疗癌性疼痛的药物组合物,所述药物组合物由下述重量份的原料制备得到:芦笋10份、生附子12份、白屈菜9份、三七5份、马钱子1份、生草乌6份;
所述药物组合物的制备方法,其特征在于,包括以下步骤:
步骤1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;
步骤2)然后按重量份取用芦笋、白屈菜、三七,并加入到步骤1所得初加工液体中,进行两次煎煮;第一次煎煮时,加水量为原料总重量的3-5倍,煎煮60min,过滤后取其滤液;第二次煎煮时,加水量为原料总重量的3-4倍,煎煮50min,过滤后取其滤液;将两次所得滤液合并,得煎煮提取液;
步骤3)将步骤2所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
实施例4药物毒性实验
1、实验材料
1.1实验动物:ICR小鼠44只,雌雄各半,购于北京海淀兴旺实验动物养殖场,许可证编号SCXK-(军)2007-004。
1.2药品试剂
1)本发明所制备药物组合物,本品为液体。
将44只按体重与性别随机分成实验组和对照组,每组22只,雌雄各半,实验前禁食不禁水12h。
实验组灌胃给予本发明所制备药物组合物液体,按48g/kg标准,分两次给药,其中间隔4h;
对照组给等量的常水,给药后连续观察7日,每日观察比较两组小鼠的外观、行为活动、精神状态、呼吸变化,隔日称一次体重。
结果显示:给药后7日内,动物未见死亡,一般状况良好,毛色正常,无立毛,饮食正常、小便正常,大便为干燥成行,无腹泻溏泄,呼吸正常,活动自如,无异常行为表现;
小鼠体重增长正常,未见其它明显异常反应,且其处死解剖,发现其主要脏器未见明显异常,故该药物属于无毒级。
实施例5动物止痛实验
1、实验材料
1.1实验动物:ICR小鼠90只,雌雄兼用,购于北京海淀兴旺实验动物养殖场,许可证编号SCXK-(军)2007-004。
1.2药品试剂
1)本发明所制备药物组合物;
2)阳性对照药:市售止痛药物;
3)冰乙酸(HAc),分析纯。
2、实验方法
2.1试剂配制
将0.6%冰乙酸用生理盐水溶液配制,具体方法为:准确吸取100%的冰醋酸0.3ml,溶于pH 7-7.2的生理盐水溶液50ml中。
2.2实验小鼠90只,平均分为对照组,市售止痛药物组(67mg/kg),药物组合物大、中、小剂量组(分别为8.4g/kg、4.2g、2.1g/kg,相对于临床人用量的20倍、10倍和5倍),每组18只,分别给予等体积溶媒、市售止痛药物和不同剂量的药物组合物口服液;
各实验组给药后1h,随即腹腔注射0.6%HAc生理盐水溶液0.2m/只,观察30分钟内小鼠扭体反应次数(腹部内凹,伸展后肢,臀部抬高)和扭体反应率并记录结果,按下式计算各组镇痛百分率,其中给药组包括市售止痛药物组、药物组合物大、中、小剂量组;
统计学处理采用SPSS软件进行组间t检验。结果表明:市售止痛药物及药物组合物大、中、小三个剂量均能显著减少冰醋酸引起的小鼠扭体反应的次数(p<0.05,p<0.01),且随着镇痛效果随药物的剂量增加而增加。
实施例6临床实验
1.1实验内容
本组40例癌性疼痛患者男28例,女12例,最小年龄28岁,最大年龄72岁,平均50岁。其中肺癌10例、肝癌16例、胃癌8例、胰腺癌6例,中度疼痛22例,重度疼痛18例,全部病例均经影像学、胃镜、CT及病理组织检查,诊断明确,有中重度疼痛,无明显肝肾功能障碍者,患者神志清楚,能够配合观察治疗。
用药方法:每日三次,每次20毫升,半空腹口服。
1.2疼痛分级标准
根据文献资料,将疼痛分为4级:
0级:无疼痛;
I级:(轻度疼痛)疼痛可忍受,但不影响日常生产及睡眠;
II级:(中度疼痛),疼痛明显,不能忍受,日常生活及睡眠受至影响,要求服用镇痛药;
III级:(重度疼痛)疼痛激烈,不能忍受,需要镇痛药,睡眠严重受到干扰。
1.3疗效标准
治疗后缓解程度一般分为4级:
1)完全缓解(CR)无疼痛;
2)部分缓解:(PR)疼痛较给药前明显减轻,睡眠基本不受干扰,能正常生活;
3)轻微疗效:(MR)疼痛较给药前减轻,但有明显疼痛,睡眠受到干扰;
4)无效:(NR)与给药前比较无减轻疼痛。
1.4实验结果
患者服用癌痛定口服液后,有22例在8-12小时,疼痛开始减轻,直到疼痛消失,CR率为55例;部分缓解例,PR率为22.5%;轻微疗效5例,MR率为12.5%,无效4例;NR率为10%,总有效率为90%;
取得效果时间最快8小时,最慢24小时,平均16小时。两组发病年龄、疼痛类型及程度均有可比性(P>0.05)。
以上对本发明及其实施方式进行了描述,这种描述没有限制性。总而言之如果本领域的普通技术人员受其启示,在不脱离本发明创造宗旨的情况下,不经创造性的设计出与该技术方案相似的结构方式及实施例,均应属于本发明的保护范围。
Claims (5)
1.一种治疗癌性疼痛的药物组合物,其特征在于,所述药物组合物由下述重量份的原料制备得到:芦笋5-10份、生附子10-12份、白屈菜5-9份、三七3-5份、马钱子0.6-1份、生草乌3–6份。
2.根据权利要求1所述的一种治疗性疼痛的药物组合物,其特征在于,所述药物组合物由下述重量份的原料制备得到:芦笋5份、生附子10份、白屈菜5份、三七3份、马钱子0.6份、生草乌3份。
3.根据权利要求1所述的一种治疗癌性疼痛的药物组合物,其特征在于,所述药物组合物由下述重量份的原料制备得到:芦笋7份、生附子11份、白屈菜7份、三七4份、马钱子0.8份、生草乌4份。
4.根据权利要求1所述的一种治疗癌性疼痛的药物组合物,其特征在于,所述药物组合物由下述重量份的原料制备得到:芦笋10份、生附子12份、白屈菜9份、三七5份、马钱子1份、生草乌6份。
5.根据权利要求1-4任意一项所述的药物组合物的制备方法,其特征在于,包括以下步骤:
步骤1)首先按重量份取用生附子、马钱子、生草乌,清洗后放入水中,煎煮一小时,得初加工液体;
步骤2)然后按重量份取用芦笋、白屈菜、三七,并加入到步骤1所得初加工液体中,进行两次煎煮;第一次煎煮时,加水量为原料总重量的3-5倍,煎煮60min,过滤后取其滤液;第二次煎煮时,加水量为原料总重量的3-4倍,煎煮50min,过滤后取其滤液;将两次所得滤液合并,得煎煮提取液;
步骤3)将步骤2所得煎煮提取液静置沉淀24h后,经过滤后取其纯清液体;然后再用微孔滤膜过滤器过滤,取滤液;将所得纯清液体与滤液合并后放入浓缩罐,经浓缩处理后即得。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210884533.5A CN115054664A (zh) | 2022-07-25 | 2022-07-25 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
PCT/CN2023/096579 WO2024021826A1 (zh) | 2022-07-25 | 2023-05-26 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210884533.5A CN115054664A (zh) | 2022-07-25 | 2022-07-25 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115054664A true CN115054664A (zh) | 2022-09-16 |
Family
ID=83205689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210884533.5A Pending CN115054664A (zh) | 2022-07-25 | 2022-07-25 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN115054664A (zh) |
WO (1) | WO2024021826A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024021826A1 (zh) * | 2022-07-25 | 2024-02-01 | 周田明 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371741A (zh) * | 2002-03-13 | 2002-10-02 | 张平 | 一种用于癌性疼痛镇痛的中药注射液 |
CN103239635A (zh) * | 2012-02-13 | 2013-08-14 | 周田明 | 抗癌痛口服液 |
CN107837380A (zh) * | 2017-12-12 | 2018-03-27 | 汤阴县瑞星生物有限公司 | 一种治疗癌性疼痛的中药组合物及其制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1164282C (zh) * | 2001-02-21 | 2004-09-01 | 陈祖沛 | 一种治疗肿瘤的药物及其制备方法 |
CN102008563B (zh) * | 2010-12-09 | 2012-05-23 | 湖南景民制药有限公司 | 一种抗癌中药及其配制方法 |
CN102432618B (zh) * | 2011-12-08 | 2013-12-04 | 南京海昌中药集团有限公司 | 一种从马钱子总碱中分离纯化马钱子碱的制备工艺 |
CN115054664A (zh) * | 2022-07-25 | 2022-09-16 | 北京康恩泰生物医药有限公司 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
-
2022
- 2022-07-25 CN CN202210884533.5A patent/CN115054664A/zh active Pending
-
2023
- 2023-05-26 WO PCT/CN2023/096579 patent/WO2024021826A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1371741A (zh) * | 2002-03-13 | 2002-10-02 | 张平 | 一种用于癌性疼痛镇痛的中药注射液 |
CN103239635A (zh) * | 2012-02-13 | 2013-08-14 | 周田明 | 抗癌痛口服液 |
CN107837380A (zh) * | 2017-12-12 | 2018-03-27 | 汤阴县瑞星生物有限公司 | 一种治疗癌性疼痛的中药组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
邓旭坤 等: "马钱子治疗癌性疼痛的基础研究及临床应用" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024021826A1 (zh) * | 2022-07-25 | 2024-02-01 | 周田明 | 一种治疗癌性疼痛的药物组合物及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2024021826A1 (zh) | 2024-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN102772781B (zh) | 一种治疗慢性结肠炎的中药制剂及其制备方法 | |
CN115054664A (zh) | 一种治疗癌性疼痛的药物组合物及其制备方法 | |
CN102106980B (zh) | 一种治疗尿毒症的药物及制备方法 | |
CN111588827A (zh) | 治疗癌性胸、腹水的外用利水膏剂及其制备方法 | |
CN107496525B (zh) | 一种治疗癌性疼痛疾病的中药组合物及其应用 | |
CN101361885B (zh) | 一种用于治疗前列腺疾病的中药制剂及其制备方法 | |
CN100460004C (zh) | 一种治疗癌瘤的药酒及制备方法 | |
WO2005074952A1 (fr) | Medicament chinois pour le traitement du syndrome du colon irritable ainsi que preparation de celui-ci | |
CN108815448B (zh) | 一种治疗慢性结肠炎的中药颗粒剂 | |
CN102274428B (zh) | 一种具有治疗肠易激综合症作用的药物组合物及其制备方法和应用 | |
CN101869700B (zh) | 一种治疗肿瘤的中药口服液及其制备方法 | |
CN1330366C (zh) | 痔疮膏及其制备方法 | |
CN112190681A (zh) | 一种治疗溃疡性结肠炎的中药组合物及其制备方法 | |
CN104042916A (zh) | 一种治疗糖尿病症的苦瓜中药制剂及制备方法 | |
US5702728A (en) | Clam extract preparation, the method of preparation and use thereof | |
CN116270834B (zh) | 一种用于治疗胃肠功能紊乱的中药复方制剂及其制备方法和应用 | |
CN1068223C (zh) | 治肝丸 | |
CN116270949A (zh) | 一种降低高尿酸的中药组合物及其制备方法 | |
CN1850201A (zh) | 一种治疗口腔溃疡的中药外用药的制备方法 | |
CN116236533A (zh) | 一种治疗功能性腹胀和癌性腹胀的中药组合物及其应用 | |
CN118806858A (zh) | 痛风贴套组及其制备方法 | |
CN114748562A (zh) | 一种辅助治疗癌性腹水的中药组合物及其制备方法和用途 | |
CN104435950A (zh) | 一种治疗上消化道出血症的中药止血散及其制备方法 | |
CN115282202A (zh) | 一种治疗腺性膀胱炎的中药及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220916 |